

## **Decree**

**No .../2024 (... . . .) of the Minister of Interior**

**amending Decree No 78/2022 of the Ministry of Interior of 28 December 2022 on  
controlled substances**

Based on the authorisation granted in Section 32(5a) of Act XCV of 2005 on medicinal products for human use and on the amendment of other regulations related to medicinal products, and acting within my duties as defined in Section 66(1)(26) of Government Decree No 182/2022 of 24 May 2022 on the duties and powers of members of the Government, I hereby order the following:

### **Section 1**

Annex 3 of Decree No 78/2022 of the Ministry of Interior of 28 December 2022 on controlled substances (hereinafter referred to as ‘the Decree’) is amended in accordance with *Annex 1* hereto.

### **Section 2**

This Decree shall enter into force on the third day following its publication.

### **Section 3**

The requirement for the prior notification of this draft decree, as stipulated in Articles 5 to 7 of Directive (EU) 2015/1535 of the European Parliament and of the Council of 9 September 2015 laying down a procedure for the provision of information in the field of technical regulations and of rules on Information Society services, has been met.

Dr. Sándor Pintér  
Minister of Interior

1. The following rows 327 to 340 are added to the table in point 6.1 of Annex 3 of the Decree:

	(A	B	C	D
1	Official name (or other name or abbreviation, or another type of spelling commonly used abroad)	Chemical name	Molecular formula	InChIKey chemical identifier)

“

327	ADMB-3TMS-PRINACA	N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(3-(trimethylsilyl)propyl)-1H-indazole-3-carboxamide	C <sub>20</sub> H <sub>32</sub> N <sub>4</sub> O <sub>2</sub> Si	LJKMOYFTWIBFJI-UHFFFAOYSA-N
328	N-cyclohexyl butylone	1-(1,3-benzodioxol-5-yl)-2-(cyclohexylamino)butan-1-one	C <sub>17</sub> H <sub>23</sub> NO <sub>3</sub>	JUIRPSMGWVYMJT-UHFFFAOYSA-N
329	2'-Fluoro-2-fluoro-3-methylfentanyl	N-(1-(2-fluorophenethyl)-3-methylpiperidin-4-yl)-N-(2-fluorophenyl)propionamide	C <sub>23</sub> H <sub>28</sub> F <sub>2</sub> N <sub>2</sub> O	ZHMCEQBHANQWEW-UHFFFAOYSA-N
330	Etomethazene	2-[(4-ethoxyphenyl)methyl]-N,N-diethyl-5-methyl-1H-benzimidazole-1-ethanamine	C <sub>23</sub> H <sub>31</sub> N <sub>3</sub> O	ZARKNPABJGEOQ-UHFFFAOYSA-N
331	Ethyleneoxynitazene	2-{2-[(2,3-dihydro-1-benzofuran-5-yl)methyl]-5-nitro-1H-benzimidazol-1-yl}-N,N-diethylethan-1-amine	C <sub>22</sub> H <sub>26</sub> N <sub>4</sub> O <sub>3</sub>	IPSJQZUMCSELFZ-UHFFFAOYSA-N
332	iso-3-MMC	1-(methylamino)-1-(3-methylphenyl)propan-2-one	C <sub>11</sub> H <sub>15</sub> NO	QXBFBMKWNOHDFB-UHFFFAOYSA-N
333	1cP-Al-LAD	4-(cyclopropanecarbonyl)-N,N-diethyl-7-(prop-2-en-1-yl)-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide	C <sub>26</sub> H <sub>31</sub> N <sub>3</sub> O <sub>2</sub>	VSABTUDYQCMWKE-UHFFFAOYSA-N
334	CUMYL-3TMS-PRINACA	N-(2-phenylpropan-2-yl)-1-(3-(trimethylsilyl)propyl)-1H-indazole-3-carboxamide	C <sub>23</sub> H <sub>31</sub> N <sub>3</sub> OSi	BFLYAEBVCZMSPK-UHFFFAOYSA-N
335	NMDMSB	1-Naphthyl 4-methyl-3-(dimethylsulfamoyl)-	C <sub>20</sub> H <sub>19</sub> NO <sub>4</sub> S	PNUYASIDNIWYQI-

		benzoate		UHFFFAOYSA-N
336	tetrahydrocannabidiol (H4-CBD)	2-(2-isopropyl-5-methylcyclohexyl)-5-pentylbenzene-1,3-diol	C <sub>21</sub> H <sub>34</sub> O <sub>2</sub>	LXIXAVCVBZBXIY-UHFFFAOYSA-N
337	tetrahydrocannabiphorol (THCP)	3-Heptyl-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran-1-ol	C <sub>23</sub> H <sub>34</sub> O <sub>2</sub>	OJTMRZHYZMZJXX-UHFFFAOYSA-N
338	4'-chloro deschloroalprazolam	6-(4-chlorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine	C <sub>17</sub> H <sub>23</sub> NO <sub>3</sub>	QZQFCOLCRXZSIK-UHFFFAOYSA-N
339	protonitazepine	5-nitro-2-[(4-propoxyphenyl)methyl]-1-(2-pyrrolidin-1-ylethyl)benzimidazole	C <sub>23</sub> H <sub>28</sub> N <sub>4</sub> O <sub>3</sub>	KCRWXNIIIXGBPID-UHFFFAOYSA-N
340	1T-LSD	N,N-Diethyl-7-methyl-4-(thiophene-2-carbonyl)-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide	C <sub>25</sub> H <sub>27</sub> N <sub>3</sub> O <sub>2</sub> S	UKYJDWQKFQDRRX-UHFFFAOYSA-N

”